Navigation Links
Ambit and Astellas Announce Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the 54th Annual Meeting of the American Society of Hematology
Date:12/10/2012

y is to define the maximum tolerated dose of quizartinib when given as maintenance therapy after treatment with an allogeneic HSCT.  Patient enrollment is ongoing.

About Quizartinib
Quizartinib (AC220) is a novel, potent, highly selective, orally bioavailable FMS-like tyrosine kinase-3 (FLT3) inhibitor being developed in collaboration between Ambit Biosciences Corporation and Astellas Pharma Inc. Quizartinib is currently under evaluation in a Phase 2b clinical trial as monotherapy treatment for adult patients with relapsed or refractory AML, and in two Phase 1 studies in a combination treatment regimen with chemotherapy, and as a maintenance therapy following transplant, respectively.

About Ambit Biosciences
Ambit Biosciences is a privately held biopharmaceutical company engaged in the development of a robust pipeline of small molecule kinase inhibitors for the treatment of cancer, inflammatory disease and other indications. Ambit's lead compound, quizartinib (AC220), is a novel, potent, highly selective, orally bioavailable FMS-like tyrosine kinase-3 (FLT3) inhibitor, and is currently under clinical investigation in patients with relapsed or refractory AML and treatment-naive AML. Ambit is developing quizartinib in collaboration with Astellas Pharma Inc. as part of a worldwide agreement to jointly develop and commercialize FLT3 kinase inhibitors in oncology and non-oncology indications. In addition to quizartinib, Ambit's clinical pipeline includes AC430, an oral JAK2 inhibitor, and CEP-32496, a BRAF inhibitor licensed to Teva. Ambit's preclinical portfolio includes a proprietary CSF1R inhibitor program. For more information, visit www.ambitbio.com.

About Astellas Pharma Inc.
Astellas Pharma Inc., located in Tokyo, Japan, is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceuticals. Astellas
'/>"/>

SOURCE Ambit Biosciences
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Ambit Biosciences Completes $50 Million Financing to Advance Lead Drug Candidate in Acute Myeloid Leukemia
2. Ambit Biosciences and Teva Announce Clearance of an Investigational New Drug (IND) Application for CEP-32496, A Novel BRAF(V600E) Inhibitor
3. Astellas Announces Acceptance of U.S. New Drug Application for Tacrolimus Extended Release Capsules
4. Personal Connections Drive Employee Participation For Changing Tomorrow Day at Astellas
5. Astellas to Close Urogenix, North Carolina-based Urology Research Facility
6. Astellas and Fujita Health University Discover Neuronal Maturation Deficits in Patients Suffering from Schizophrenia and Bipolar Disorder
7. First sales of DIFICLIR™ by Astellas Pharma Europe triggers 10 Million Euro Milestone Payment to Optimer Pharmaceuticals
8. Xstelos Holdings Announces Dividend
9. Medbox, Inc. Announced Increased Funding for Corporate Giving Program in 2013
10. Biogen Idec and Isis Pharmaceuticals Announce Collaboration For Antisense Programs To Treat Neurological Disorders
11. IRIDEX Corporation Announces Preliminary Results of its Tender Offer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... , July 20, 2015 Research and ... of the "D-dimer Testing Market - Global ... Forecast 2014 - 2022" report to their ... vitro diagnostics market is one of the fastest ... attributed to the improved health care awareness, preference ...
(Date:7/27/2015)... -- Dynatronics Corporation (NASDAQ: DYNT ) today announced it has ... approval allows the company to sell these products in ... "Receiving the CE Mark represents the achievement of an important ... Jr. , president and CEO of Dynatronics. "Over the past several ... , Japan , Mexico ...
(Date:7/27/2015)... British Columbia and MENLO ... --  DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" ... developing and commercializing proven cancer therapies in new ... accepted subscriptions from institutional and accredited investors for ... shares of common stock and 3.35 million common ...
Breaking Medicine Technology:D-dimer Testing Market - Global Industry Analysis 2015 2D-dimer Testing Market - Global Industry Analysis 2015 3Dynatronics Awarded CE Mark Approval for Its Solaris Products 2DelMar Pharmaceuticals Announces Financing Update and Initial Subscriptions of $2.0 million in Registered Direct Offering 2DelMar Pharmaceuticals Announces Financing Update and Initial Subscriptions of $2.0 million in Registered Direct Offering 3
... Dec. 8, 2010 Reportlinker.com announces that a new ... Europe Neurology Devices Market Outlook to 2016 ... Neurology Devices Market Outlook to 2016 ... 2016" provides key market data on the Europe Neurology ...
... Reportlinker.com announces that a new market research ... Asia-Pacific Dental Devices Market Outlook to 2016 ... Asia-Pacific Dental Devices Market Outlook to 2016 ... Devices Market Outlook to 2016" provides key market ...
Cached Medicine Technology:Reportlinker Adds Europe Neurology Devices Market Outlook to 2016 2Reportlinker Adds Europe Neurology Devices Market Outlook to 2016 3Reportlinker Adds Europe Neurology Devices Market Outlook to 2016 4Reportlinker Adds Europe Neurology Devices Market Outlook to 2016 5Reportlinker Adds Europe Neurology Devices Market Outlook to 2016 6Reportlinker Adds Europe Neurology Devices Market Outlook to 2016 7Reportlinker Adds Europe Neurology Devices Market Outlook to 2016 8Reportlinker Adds Europe Neurology Devices Market Outlook to 2016 9Reportlinker Adds Europe Neurology Devices Market Outlook to 2016 10Reportlinker Adds Europe Neurology Devices Market Outlook to 2016 11Reportlinker Adds Europe Neurology Devices Market Outlook to 2016 12Reportlinker Adds Europe Neurology Devices Market Outlook to 2016 13Reportlinker Adds Europe Neurology Devices Market Outlook to 2016 14Reportlinker Adds Europe Neurology Devices Market Outlook to 2016 15Reportlinker Adds Asia-Pacific Dental Devices Market Outlook to 2016 2Reportlinker Adds Asia-Pacific Dental Devices Market Outlook to 2016 3Reportlinker Adds Asia-Pacific Dental Devices Market Outlook to 2016 4Reportlinker Adds Asia-Pacific Dental Devices Market Outlook to 2016 5Reportlinker Adds Asia-Pacific Dental Devices Market Outlook to 2016 6Reportlinker Adds Asia-Pacific Dental Devices Market Outlook to 2016 7Reportlinker Adds Asia-Pacific Dental Devices Market Outlook to 2016 8Reportlinker Adds Asia-Pacific Dental Devices Market Outlook to 2016 9Reportlinker Adds Asia-Pacific Dental Devices Market Outlook to 2016 10Reportlinker Adds Asia-Pacific Dental Devices Market Outlook to 2016 11Reportlinker Adds Asia-Pacific Dental Devices Market Outlook to 2016 12Reportlinker Adds Asia-Pacific Dental Devices Market Outlook to 2016 13Reportlinker Adds Asia-Pacific Dental Devices Market Outlook to 2016 14Reportlinker Adds Asia-Pacific Dental Devices Market Outlook to 2016 15
(Date:7/27/2015)... (PRWEB) , ... July 27, 2015 , ... ... Treatment Center has added hiking to its options. Already an industry ... Palms is constantly on the lookout for the latest successful trends in helping ...
(Date:7/27/2015)... ... July 27, 2015 , ... At Champagne Smiles, they know that tooth ... can incur a lot of stress, pain, discomfort and embarrassment, which is why they ... treatment reaps the benefits of implants with the cost savings of dentures for anyone ...
(Date:7/27/2015)... ... July 27, 2015 , ... Hexagon Geospatial is ... to understand and share your geospatial experience. These new light-weight applications cohesively combine ... distinct business problems. , “Our world is more dynamic than it has ever ...
(Date:7/27/2015)... (PRWEB) , ... July 27, 2015 , ... Boston IVF, ... birth, will host an educational "Happy Hour" on Nantucket Island for women who ... August 6 at Grey Lady Restaurant and Bar, 2 Chins Way, Nantucket Island 02554 ...
(Date:7/27/2015)... ... 27, 2015 , ... Rountree Brady Insurance Agency, a locally ... new charity drive to support Next Generation, a volunteer group that works to ... , Next Generation workers are dedicated to improving the lives and outlooks of ...
Breaking Medicine News(10 mins):Health News:Hiking Adds Benefits to Recovery at Serenity Palms 2Health News:Hiking Adds Benefits to Recovery at Serenity Palms 3Health News:NJ Top Dentists Presents, Dr. Richard Champagne of Champagne Smiles! 2Health News:NJ Top Dentists Presents, Dr. Richard Champagne of Champagne Smiles! 3Health News:NJ Top Dentists Presents, Dr. Richard Champagne of Champagne Smiles! 4Health News:Hexagon Geospatial Visualizes Stories with the Hexagon Smart M.App® 2Health News:Hexagon Geospatial Visualizes Stories with the Hexagon Smart M.App® 3Health News:Boston IVF to Host Egg Freezing Event in Nantucket on August 6th at 4:30pm 2Health News:Boston IVF to Host Egg Freezing Event in Nantucket on August 6th at 4:30pm 3Health News:Rountree Brady Announces Charity Effort to Support Children’s Services at the Memorial University Medical Center Hospital 2Health News:Rountree Brady Announces Charity Effort to Support Children’s Services at the Memorial University Medical Center Hospital 3
... ... Management Project , ... Chicago (PRWEB) June 11, 2009 -- The Critical Access Hospital (CAH) Quality Network of ... healthcare risk, quality and patient safety software and consulting services have joined forces to ...
... it) more, experts say, , THURSDAY, June 11 (HealthDay News) -- ... shape, all you need is a four-legged pal. , Dr. ... Northwestern University,s Feinberg School of Medicine, said that dogs make great ... are natural exercise machines on a leash," he said. , Research ...
... DENVER, June 11 Birner Dental Management Services, Inc. ... PERFECT TEETH dental practices, announced its regular quarterly ... quarterly cash dividend of 17 cents per share of common ... shareholders of record June 26, 2009. , , Birner ...
... strong record of revenue growth and sales force development , ... Bulletin Board: XELR), a provider of functional foods, beverages and ... for the role of Vice President - Strategy and Network ... of XELR8 said, "We are excited to add Kevin,s strong ...
... , SAN DIEGO, June 11 Orexigen(R) Therapeutics, Inc. ... on the treatment of obesity, today announced the licensing ... expands the Company,s IP position underlying Contrave, its lead ... , "This license agreement with GSK complements the IP ...
... Wis., June 11 Health plan transparency has gained ... "quest" to have better information to make informed health ... quality is often discussed in the form of better ... in reporting on member and claims disruption. The health ...
Cached Medicine News:Health News:North Dakota Critical Access Hospital Quality Network Moves Forward with Statewide Information Management Project to Enhance Patient Safety in the State 2Health News:North Dakota Critical Access Hospital Quality Network Moves Forward with Statewide Information Management Project to Enhance Patient Safety in the State 3Health News:Need a Walking Partner? Try a Dog 2Health News:Need a Walking Partner? Try a Dog 3Health News:XELR8 Holdings, Inc. Hires Vice President of Strategy and Network Development 2Health News:XELR8 Holdings, Inc. Hires Vice President of Strategy and Network Development 3Health News:Orexigen(R) Therapeutics Announces In-Licensing of Key Patents to Further Strengthen its Intellectual Property Estate for Contrave(R) 2Health News:Orexigen(R) Therapeutics Announces In-Licensing of Key Patents to Further Strengthen its Intellectual Property Estate for Contrave(R) 3Health News:Moving Beyond the Mysteries of Disruption Reporting 2
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
Medicine Products: